Brodaty, H; Breteler, M M B; Dekosky, S T; Dorenlot, P; Fratiglioni, L; Hock, C; Kenigsberg, P A; Scheltens, P; De Strooper, B (2011). The world of dementia beyond 2020. Journal of the American Geriatrics Society, 59(5):923-927.
Full text not available from this repository.
Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments-mainly targeting the amyloid pathway, tau protein, and immunotherapy-that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia-modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Psychiatric University Hospital Zurich > Division of Psychiatric Research and Clinic for Psychogeriatric Medicine|
|DDC:||610 Medicine & health|
|Deposited On:||10 Feb 2012 21:26|
|Last Modified:||28 Nov 2013 00:25|
|ISSN:||0002-8614 (P) 1532-5415 (E)|
|Citations:||Web of Science®. Times Cited: 12|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page